[{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"2ede59b9-f8a7-4ea2-873c-71d302f69b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560416","created_at":"2021-01-18T06:36:36.789Z","updated_at":"2024-07-02T16:35:06.809Z","phase":"Phase 2","brief_title":"Fulvestrant With or Without Ganetespib in HR+ Breast Cancer","source_id_and_acronym":"NCT01560416","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • ganetespib (ADX-1612)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-30"},{"id":"fab06802-4790-49ac-8add-eadb832847c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01167114","created_at":"2021-01-18T04:39:14.334Z","updated_at":"2024-07-02T16:35:30.627Z","phase":"Phase 2","brief_title":"STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer","source_id_and_acronym":"NCT01167114","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HSP90AA1","pipe":"","alterations":" ","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 04/01/2017","study_completion_date":" 04/01/2017","last_update_posted":"2023-11-02"},{"id":"8c103644-1176-42a6-848c-96531a290601","acronym":"","url":"https://clinicaltrials.gov/study/NCT01579994","created_at":"2021-01-18T06:43:34.807Z","updated_at":"2024-07-02T16:36:36.694Z","phase":"Phase 1","brief_title":"Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers","source_id_and_acronym":"NCT01579994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ALK translocation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 04/16/2012","start_date":" 04/16/2012","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2020-12-30"},{"id":"38f7e812-7b2f-4a13-9f7b-f337348cbfb4","acronym":"SARC023","url":"https://clinicaltrials.gov/study/NCT02008877","created_at":"2021-01-18T09:10:25.745Z","updated_at":"2024-07-02T16:36:59.593Z","phase":"Phase 1/2","brief_title":"SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)","source_id_and_acronym":"NCT02008877 - SARC023","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • sirolimus • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2019-05-15"},{"id":"30af6c5b-69c6-4fd7-9cfb-43b1da4df1b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01200238","created_at":"2021-01-18T04:48:32.724Z","updated_at":"2024-07-02T16:37:05.964Z","phase":"Phase 2","brief_title":"STA-9090(Ganetespib) in Metastatic Ocular Melanoma","source_id_and_acronym":"NCT01200238","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MET • HSP90AA1","pipe":" | ","alterations":" MET expression","tags":["MET • HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 09/17/2010","start_date":" 09/17/2010","primary_txt":" Primary completion: 10/12/2014","primary_completion_date":" 10/12/2014","study_txt":" Completion: 11/11/2016","study_completion_date":" 11/11/2016","last_update_posted":"2018-10-18"},{"id":"368a0113-4719-4eb5-9c5b-b085f9138aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02060253","created_at":"2021-01-18T09:29:26.595Z","updated_at":"2025-02-25T14:00:25.042Z","phase":"Phase 1","brief_title":"Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer","source_id_and_acronym":"NCT02060253","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-06-14"},{"id":"bd9c14ed-7607-4b54-88c2-6373b244db33","acronym":"","url":"https://clinicaltrials.gov/study/NCT02637375","created_at":"2021-01-18T12:49:38.628Z","updated_at":"2024-07-02T16:37:31.624Z","phase":"","brief_title":"A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02637375","lead_sponsor":"University of Chicago","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • ganetespib (ADX-1612)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-05-30"}]